Inhibitors of topoisomerase II enzymes: a unique group of environmental mutagens and carcinogens.
Many inhibitors of topoisomerase II enzymes are potent mutagens, leading to major chromosomal deletions, illegitimate recombination and aneuploidy. There is increasing evidence that they are also human carcinogens. However, their lack of chemical reactivity means that they may give weak or negative results in commonly used mutagenicity tests, or may give data with characteristics quite distinct from chemicals that alkylate DNA. They do not form DNA adducts and assays such as 32P-postlabelling will not detect their presence in the body. They are generally not point mutagens and may fail to provide distinctive fingerprints in mutation spectra. These characteristics may be limiting a realistic evaluation of their role in human carcinogenesis using current methodologies.
Ferguson
L R
LR
Cancer Research Laboratory, University of Auckland Medical School, Private Bag 92019, Auckland 1000, New Zealand. l.ferguson@auckland.ac.nz
D000818:Animals; D015197:Carcinogenicity Tests; D002274:Carcinogens, Environmental / Q000737:chemistry / Q000633:toxicity*; D004247:DNA / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000633:toxicity*; D006801:Humans; D009153:Mutagens / Q000737:chemistry / Q000633:toxicity*; D059005:Topoisomerase II Inhibitors
D002274:Carcinogens, Environmental; D004791:Enzyme Inhibitors; D009153:Mutagens; D059005:Topoisomerase II Inhibitors; D004247:DNA